Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis

Published:2017-03-23 Issue:2 Volume:8 Page:129-137
ISSN:1759-1961
Container-title:Clinical and Experimental Neuroimmunology
language:en
Short-container-title:Clin Exp Neuroimmunol

Author:

Yamamura Takashi¹,Ashtamker Natalia²,Ladkani David²,Fukazawa Toshiyuki³,Houzen Hideki⁴,Tanaka Masami⁵⁶⁷,Miura Toshiro⁸,Knappertz Volker⁹¹⁰

Affiliation:

1. Department of Immunology; National Center of Neurology and Psychiatry; National Institute of Neuroscience, and Multiple Sclerosis Center; Tokyo Japan

2. Research and Development; Teva Pharmaceutical Industries; Netanya Israel

3. Sapporo Neurology Hospital; Sapporo Japan

4. Department of Neurology; Obihiro Kosei General Hospital; Hokkaido Japan

5. Multiple Sclerosis Center; Kyoto Min-iren Chuo Hospital; Kyoto Japan

6. Department of Neurology; Kaikoukai Josai Hospital; Nagoya Japan

7. Department of Neurology; School of Medicine; Fujita Health University; Aichi Japan

8. Research and Development; Teva Pharmaceutical K.K.; Tokyo Japan

9. Research and Development; Teva Pharmaceutical Industries; Frazer PA USA

10. Department of Neurology; Heinrich Heine University; Düsseldorf Germany

Funder

Teva Pharmaceutical Industries

Publisher

Wiley

Subject

Neurology (clinical),Immunology and Microbiology (miscellaneous),Immunology,Neuroscience (miscellaneous)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cen3.12383/fullpdf

Reference32 articles.

1. World Health Association Atlas: Multiple Sclerosis Resources in the World 2008

2. Genetic and environmental factors underlying the rapid changes in epidemiological and clinical features of multiple sclerosis and neuromyelitis optica in Japanese;Kira;Clin Exp Neuroimmunol,2013

3. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability;Stefano;Arch Neurol,2001

4. Glatiramer in the treatment of multiple sclerosis;Rizvi;Int J Nanomedicine,2006

5. An update on new and emerging therapies for relapsing-remitting multiple sclerosis;Weinstock-Guttman;Am J Manag Care,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease‐modifying drugs for multiple sclerosis in Japan: A focus on the 2017 Japanese guidelines and the 2018 supplement;Clinical and Experimental Neuroimmunology;2019-03

2. Long‐term, single‐arm, open‐label, multicenter phase 2/4 study of glatiramer acetate by subcutaneous injection in Japanese patients with relapsing–remitting multiple sclerosis;Clinical and Experimental Neuroimmunology;2018-11-19

3. Diagnostic accuracy of semiautomatic lesion detection plus quantitative susceptibility mapping in the identification of new and enhancing multiple sclerosis lesions;NeuroImage: Clinical;2018